RMDのチャート
RMDの企業情報
| symbol | RMD |
|---|---|
| 会社名 | ResMed Inc. （RMD レスメド） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 レスメド（ResMed Inc.）は持株会社である。同社は睡眠呼吸障害（SDB）、慢性閉塞性肺疾患（COPD）、神経筋疾患および呼吸器疾患を診断、治療および管理する医療機器およびクラウドベースのソフトウェアアプリケーションの開発、製造、流通および販売に従事する。SDBには、閉塞性睡眠時無呼吸（OSA）および睡眠中に生じる他の呼吸器障害が含まれる。クラウドベースのソフトウェアデジタルヘルスアプリケーションとその機器は患者のアウトカムを改善するために接続されたケアを提供するように設計される。同社の製品ポートフォリオには、機器、診断製品、マスクシステム、ヘッドギアおよびその他のアクセサリ、歯科用デバイス、ポータブル酸素濃縮器（POC）、クラウドベースのソフトウェアインフォマティクスソリューションが含まれる。同社はSDBの治療のための継続的陽性気道内圧（CPAP）、可変陽性気道内圧（VPAP）およびAutoSetシステムを製造する。 レスメドは米国の医療機器メ―カ―持株会社。子会社を通じ、睡眠呼吸障害（SDB）およびその他の呼吸器疾患を治療、診断、管理するための医療機器を開発、製造、販売。SDBは閉塞性睡眠時無呼吸（OSA）、および睡眠中に発生する他の呼吸器障害を含む。気流発生装置、診断製品、マスクシステム、ヘッドギアやその他の付属品などを取り扱う。本社はサンディエゴ。 at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. |
| 本社所在地 | 9001 Spectrum Center Blvd. San Diego CA 92123 USA |
| 代表者氏名 | Robert Andrew Douglas |
| 代表者役職名 | President Chief Operating Officer |
| 電話番号 | +1 858-746-2400 |
| 設立年月日 | 34394 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 5940人 |
| url | www.resmed.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 748.78800 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 14898.90000 |
| 売上高 | 売上高（百万ドル） 2454.64300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15946.91000 |
| 当期純利益 | 当期純利益（百万ドル） 462.88200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 31 December 2018 ResMed Inc. revenues increased 10% to $1.24B. Net income before extraordinary items increased 4% to $231.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Selling general and administrative increase of 4% to $308.9M (expense) Interest income decrease of 83% to $1.6M (income). |
RMDのテクニカル分析
RMDのニュース
Here''s How Much You Would Have Made Owning ResMed Stock In The Last 10 Years 2023/05/26 19:00:53 Benzinga
ResMed (NYSE: RMD ) has outperformed the market over the past 10 years by 6.02% on an annualized basis producing an average annual return of 15.76%. Currently, ResMed has a market capitalization of $31.65 billion. Buying $1000 In RMD: If an … Full story available on Benzinga.com
ResMed Inc.: 3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023 2023/05/25 13:10:00 Finanz Nachrichten
France''s Jean-Louis Pépin and Germany''s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSAGermany''s Michael Arzt present…
UBS initiates coverage of ResMed at ''buy'' 2023/05/22 14:14:33 Investing.com
https://www.investing.com/news/pro/resmed-inc-receives-investment-bank-analyst-rating-update-3087890
A Bullish Sign Appears On ResMed''s Chart 2023/05/17 14:49:26 Benzinga
If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE: RMD ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com
Electronic Arts, TD SYNNEX And 2 Other Stocks Insiders Are Selling 2023/05/15 12:29:01 Benzinga
The Nasdaq index closed lower on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga''s insider transactions platform. ResMed The Trade: ResMed Inc. (NYSE: RMD ) CFO Brett Sandercock sold a total of 12,574 shares at an average price of $233.13. The insider received around $2.93 million from selling those shares. What’s Happening: ResMed reported better-than-expected third-quarter EPS and sales results. What ResMed Does: ResMed is one of the largest respiratory … Full story available on Benzinga.com
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023 2023/04/06 20:05:00 GlobeNewswire
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
$1000 Invested In ResMed 5 Years Ago Would Be Worth This Much Today 2023/04/04 20:00:52 Benzinga
ResMed (NYSE: RMD ) has outperformed the market over the past 5 years by 9.07% on an annualized basis producing an average annual return of 18.39%. Currently, ResMed has a market capitalization of $32.35 billion. Buying $1000 In RMD: If an … Full story available on Benzinga.com
ResMed Inc.: ResMed Chief Administrative Officer and Global General Counsel to Retire 2023/03/30 20:10:00 Finanz Nachrichten
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed''s executive leadership team SAN DIEGO…
ResMed Chief Administrative Officer and Global General Counsel to Retire 2023/03/30 20:05:00 GlobeNewswire
SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023.
Critical Care Devices Market May See a Big Move | ResMed, CareFusion, Fresenius Kabi, Smiths Medical 2023/03/28 08:06:52 OpenPR
The Latest research study released by AMA "Worldwide Critical Care Devices Market" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers,
ResMed Inc. – Consensus Indicates Potential 19.7% Upside 2023/01/06 11:43:42 DirectorsTalk
ResMed Inc. with ticker code (RMD) now have 8 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 280 and 211 with a mean TP of 252.5. Given that the stocks previous close was at 210.9 this would imply there is a potential upside of 19.7%. The day 50 moving average is 218.88 and the 200 day MA is 220.92. The company has a market capitalisation of $30,039m. Company Website: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $35,965m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Razer''s Comfy Quest 2 VR Straps Are Made With a CPAP Manufacturer - CNET 2023/01/05 18:00:25 CNET
Razer, ResMed, and Meta could lead to new wearables and accessories down the road.
ResMed Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference 2023/01/02 21:05:00 GlobeNewswire
SAN DIEGO, Jan. 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, beginning at approximately 1:30 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA.
ResMed Inc. – Consensus Indicates Potential 10.1% Upside 2022/11/27 16:34:56 DirectorsTalk
ResMed Inc. with ticker code (RMD) have now 8 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 280 and 211 with a mean TP of 252.5. Now with the previous closing price of 229.34 this now indicates there is a potential upside of 10.1%. The 50 day moving average now sits at 220.58 and the 200 day moving average is 224.69. The market capitalisation for the company is $33,680m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $37,081m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
ResMed Inc.: ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions 2022/11/22 14:05:00 Finanz Nachrichten
- Acquisition expands ResMed''s SaaS business to Germany, first non-U.S. market - Outpatient therapy services added to ResMed''s growing SaaS offering portfolio - Purchase price of €958.6 million (US…